Andere Sprachen Kura Oncology, Inc.

Aktien

A143UH

US50127T1097

KURA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 31.05.2024			% 5 Tage	% 1. Jan.
20,61 ^USD	-0,39 %		-2,65 %	+43,32 %

24.05.	Kura Oncology, Inc. schließt Rekrutierung von 85 Patienten im Phase 2-Teil von KOMET-001 ab	CI
15.05.	Transcript : Kura Oncology, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Kura Oncology, Inc. Completes Enrollment of 85 Patients in the Phase 2 Portion of KOMET-001	24.05.
Transcript : Kura Oncology, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM	15.05.
Kura Oncology Enrolls 85 Patients in Ziftomenib Trial for Leukemia Drug	14.05.
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML	14.05.
Transcript : Kura Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024	02.05.
Kura Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02.05.
Kura Oncology, Inc. Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML	22.04.
Transcript : Kura Oncology, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 09:00 AM	14.03.
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma	06.03.
Transcript : Kura Oncology, Inc., 2023 Earnings Call, Feb 27, 2024	27.02.
Kura Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.02.
Kura Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27.02.
Kura Oncology, Inc. Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia	26.02.
Kura Oncology Says Study of Leukemia Combination Therapy Yields Positive Early Data	30.01.
Transcript : Kura Oncology, Inc. - Special Call	30.01.
Top Premarket Gainers	30.01.
Kura Oncology, Inc. Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia	30.01.
Kura Oncology Expects to Raise $150 Million in Gross Proceeds From Oversubscribed Private Placement	24.01.
Top Premarket Gainers	24.01.
KURA ONCOLOGY, INC. : Mizuho Securities favorable au dossier	22.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Kura Oncology, Inc.

Aktien

A143UH

US50127T1097

KURA

Andere Sprachen

Filter